Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry

Kidney International Supplements

Volumn 5, Issue 1, 2015, Pages 23-32

  Hamano, Takayuki ^a   Fujii, Naohiko ^a   Hayashi, Terumasa ^b   Yamamoto, Hiroyasu ^c   Iseki, Kunitoshi ^a   Tsubakihara, Yoshiharu ^a  

^a Scientific Academic Committee of the Japanese Society for Dialysis Therapy   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c Atsugi City Hospital   (Japan)

Author keywords

ESA response; ferritin; inflammation; TSAT

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; SERUM ALBUMIN; TRANSFERRIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIALYSIS; ERYTHROPOIESIS; ERYTHROPOIESIS STIMULATING AGENT RESISTANCE INDEX; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGISTER; TRANSFERRIN BLOOD LEVEL;

EID: 84930162481     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2015.6     Document Type: Article

References (40)

1. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37: S182-S238
2. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19(Suppl 2): ii1-47
3. Roger S. The CARI guidelines. Haematological targets. Iron. Nephrology (Carlton) 2006; 11(Suppl 1): S217-S229
4. KDOQI; National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47: S11-S145
5. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279-335
6. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
7. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
8. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
9. Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448
10. Toblli JE, Lombrana A, Duarte P et al. Intravenous iron reduces NT-probrain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007; 50: 1657-1665
11. McFarlane PA, Pisoni RL, Eichleay MA et al. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 2010; 78: 215-223
12. Tsubakihara Y, Nishi S, Akiba T et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010; 14: 240-275
13. Maruyama Y, Nakayama M, Yoshimura K et al. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels. Nephrol Dial Transplant 2007; 22: 1407-1412
14. Nakanishi T, Kuragano T, Kaibe S et al. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?. Clin Exp Nephrol 2012; 16: 819-826
15. Brookhart MA, Freburger JK, Ellis AR et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158
16. Bailie GR, Larkina M, Goodkin DA et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28: 2570-2579
17. Kalantar-Zadeh K, Lee GH, Miller JE et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009; 53: 823-834
18. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080
19. Pollak VE, Lorch JA, Shukla R et al. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol 2009; 10: 6
20. Gaweda AE, Bhat P, Maglinte GA et al. TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients. Hemodial Int 2014; 18: 38-46
21. Bross R, Zitterkoph J, Pithia J et al. Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. Am J Nephrol 2009; 29: 571-581
22. Kalantar-Zadeh K, Hoffken B, Wunsch H et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26: 292-299
23. Hussein S, Prieto J, O'Shea M et al. Serum ferritin assay and iron status in chronic renal failure and haemodialysis. Br Med J 1975; 1: 546-548
24. Mirahmadi KS, Paul WL, Winer RL et al. Serum ferritin level. Determinant of iron requirement in hemodialysis patients. JAMA 1977; 238: 601-603
25. Aljama P, Ward MK, Pierides AM et al. Serum ferritin concentration: a reliable guide to iron overload in uremic and hemodialyzed patients. Clin Nephrol 1978; 10: 101-104
26. Kalantar-Zadeh K, McAllister CJ, Lehn RS et al. Effect of malnutritioninflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773
27. Gaweda AE, Goldsmith LJ, Brier ME et al. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol 2010; 5: 576-581
28. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 1974; 290: 1213-1216
29. Kato A, Tsuji T, Luo J et al. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008; 28: 115-121
30. Tessitore N, Girelli D, Campostrini N et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010; 25: 3996-4002
31. Bazeley J, Bieber B, Li Y et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2452-2461
32. Nakai S, Watanabe Y, Masakane I et al. Overview of regular dialysis treatment in Japan (as of 31 December 2011). Ther Apher Dial 2013; 17: 567-611
33. Fukagawa M, Yokoyama K, Koiwa F et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013; 17: 247-288
34. Shinzato T, Nakai S, Fujita Y et al. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron 1994; 67: 280-290
35. Locatelli F, Andrulli S, Memoli B et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 991-998
36. Agarwal R, Davis JL, Smith L. Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 98-104
37. Locatelli F, Altieri P, Andrulli S et al. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial. Nephrol Dial Transplant 2012; 27: 3594-3600
38. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328: 171-175
39. Drueke TB, Eckardt KU. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 2002; 17(Suppl 5): 28-31
40. Movilli E, Cancarini GC, Zani R et al. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 2001; 16: 111-114